UPDATE: Piper Jaffray Downgrades XenoPort to Neutral on Drug Commercialization Delays

Loading...
Loading...
Piper Jaffray reduced its rating on XenoPort
XNPT
from Overweight to Neutral with a reiterated $12 price target. Piper Jaffray said, "Given the long road ahead for '829, our cautious view on the prospects for a partnership for '829 or outright sale of the company in the near-term and the lack of visibility on cash generation (i.e., continued lackluster prescription trends for Horizant and niche-like potential for arbaclofen placarbil for spasticity), we believe upside for XNPT shares is limited in the context of an enterprise value of $430M." XenoPort closed at $11.91 on Thursday.
Posted In: Analyst ColorDowngradesPrice TargetIntraday UpdateAnalyst RatingsPiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...